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Determinants of adherence to disease
modifying anti-rheumatic drugs in White
British and South Asian patients with
rheumatoid arthritis: a cross sectional study
Kanta Kumar1,2,3*, Karim Raza2,4, Peter Nightingale5, Robert Horne6, Sarah Chapman6, Sheila Greenfield1
and Paramjit Gill1
Abstract
Background: Rheumatoid arthritis (RA) is a common chronic inflammatory disease causing joint damage, disability,
and reduced life expectancy. Highly effective drugs are now available for the treatment of RA. However, poor adherence
to drug regimens remains a significant barrier to improving clinical outcomes in RA. Poor adherence has been shown to
be linked to patients’ beliefs about medicines with a potential impact on adherence. These beliefs are reported to be
different between ethnic groups. The purpose of this study was to identify potential determinants of adherence to
disease modifying anti-rheumatic drugs (DMARDs) including an assessment of the influence of beliefs about medicines
and satisfaction with information provided about DMARDs and compare determinants of adherence between RA
patients of White British and South Asian.
Methods: RA patients of either White British (n = 91) or South Asian (n = 89) origin were recruited from secondary
care. Data were collected via questionnaires on patients’: (1) self-reported adherence (Medication Adherence Report
Scale-MARS); (2) beliefs about medicines (Beliefs about Medicines Questionnaire-BMQ); (3) illness perceptions (Illness
Perceptions Questionnaire-IPQ) and (4) satisfaction with information about DMARDs (Satisfaction with Information
about Medicines questionnaire-SIMS). In addition, clinical and demographic data were collected.
Results: The results revealed that socio-demographic factors only explained a small amount of variance in adherence
whereas illness representations and treatment beliefs were more substantial in explaining non-adherence to DMARDs.
Patients’ self-reported adherence was higher in White British than South Asian patients (median 28 (interquartile range
26–30) vs median 26 (interquartile range 23–30) respectively; P = 0.013, Mann–Whitney test). Patients who reported
lower adherence were more dissatisfied with the information they had received about their DMARDs (P < 0.001,
Spearman correlation, SIMS action and usage subscale; P < 0.001, Spearman correlation, SIMS potential problems
subscale) and had more negative beliefs about their DMARDs and were related to ethnicity with South Asian patients
having more negative views about medicines.
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Conclusions: Socio-demographic factors were found to explain a small amount of variance in adherence. Illness
representations and treatment beliefs were more important in explaining non-adherence to DMARDs. Clinicians
managing South Asian patients with RA need to be aware that low adherence may be linked to negative beliefs about
medicines and illness representations of RA.
Keywords: Rheumatoid arthritis, DMARDs, Adherence, Beliefs about medicines, Illness representation, Satisfaction with
information, Ethnicity
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by an erosive synovitis [1], which can
result in joint damage, loss of joint function [2], reduced
life expectancy [3] and increased sickness absenteeism
[4]. To reduce the risk of joint damage and functional
impairment, the National Institute for Health and Clinical
Excellence (NICE) [5] has recommended the timely use of
disease-modifying anti-rheumatic drugs (DMARDs), ideally
in combination and commenced within the first three
months of symptom onset [5]. A high degree of adherence
by patients to their prescribed regimen is necessary for op-
timal outcomes [6, 7]. However, poor adherence to drug
regimens remains a significant barrier to improving clinical
outcomes in RA [8] with only 58–82 % of RA patients ad-
hering to their DMARDs [8]. Non adherence can occur
due to practical factors, such as difficulty opening medica-
tion packaging and perceptual factors such as doubts about
personal need or concerns about potential side effects [9].
Some patients experience inefficacy while others have
to stop taking DMARDs because of side effects [10, 11].
Adherence to treatment may be influenced by the pa-
tient’s social background, by their beliefs about their ill-
ness representations and beliefs about treatments [12].
Evidence suggests that beliefs about medicines that drive
non-adherence may be more prevalent in some ethnic
groups [13]. Whilst there are recognised differences in be-
liefs about medicines, the literature describing adherence
levels is scarce amongst South Asian RA patients. Our pre-
vious research has shown that, South Asian RA patients
hold more negative beliefs about DMARDs than White
British RA patients [14] and prefer traditional medicines,
such as Ayurveda, as opposed to conventional therapy
[15, 16]. Moreover, our findings suggested that patients’
evaluations of prescribed DMARDs were influenced by
how they judged their personal need for treatment rela-
tive to their concerns about potential adverse effects of
treatments. We do not, however, know the extent to
which these and other beliefs about medicines impact
on medication adherence in South Asian patients.
Other studies demonstrating an association between be-
liefs about medicines and adherence (e.g. in asthma [17],
HIV [18] and in RA [19]), have mainly been conducted
amongst Hispanic groups or European populations.
Furthermore, the literature shows that patients’ views
about specific prescribed medicines (necessity beliefs
and concerns) are influenced by more general beliefs
about pharmaceuticals as a whole and by common-sense
understandings of the illness and symptom expectations
and experiences [17, 20]. In addition, receiving adequate
information about medicines may also be crucial in pa-
tients’ decision making [21]. Thus, we wanted to identify
potential determinants of adherence to disease modifying
anti-rheumatic drugs (DMARDs) including an assessment
of the influence of beliefs about medicines and satisfaction
with information provided about DMARDs and compare
determinants of adherence between RA patients of White
British and South Asian [9].
Methods
This study was conducted in the outpatient Rheumatology
departments of Sandwell and West Birmingham Hospitals
NHS Trust, Heart of England Foundation NHS Trust and
University Hospitals Birmingham NHS Foundation Trust,
UK. Consecutive patients with RA were approached dur-
ing their normal routine rheumatology appointments. To
reduce interview bias, the researcher did not approach
any patients who were under her care. The researcher
approached patients while they were waiting to see their
consultant or nurse specialist and discussed details of the
study with them. If patients expressed an interest in taking
part, they were given a Patient Information Sheet outlin-
ing the study and time to ask questions before being asked
for their consent. Those patients who required more time
to decide were given the researcher's phone number and
asked to contact her if/when they decided to participate.
In this situation, an additional visit was required on the
part of the patients to complete the study forms. Patients
were recruited if they: (1) Self-defined themselves as
being of either White British or South Asian origin and
in addition for ‘South Asian’ origin three or more grand-
parents born in India or Pakistan; and for ‘White British’
patients had three or more grandparents born in the
UK or Ireland as outlined in our published protocol.
This approach was used in our previous work [13, 22].
(2) Fulfilled classification criteria for RA [23]. (3) Had
been taking at least one DMARD for over 3 months ac-
cording to their medical records. This cut off was chosen
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to ensure that participants had a chance to experience tak-
ing DMARDs. A number of questionnaires were used to
collect data from patients. These were the following;
1. Medication Adherence Report Scale (MARS-6).
[24, 25] This self-report measure of adherence has
demonstrated good psychometric qualities in a range
of illness groups [17, 24] and was used in the present
study to assess self-reported adherence to DMARDs.
Responses to 6 items assessing the frequency of both
unintentional (e.g. ‘I forgot’) and intentional (e.g. ‘I
decided to miss a dose’) non-adherent behaviours
were recorded using a 5-point Likert type scale.
The score range for the scale is 6 to 30 with higher
scores indicating higher reported adherence. Some
previous studies have dichotomised the MARS
scores [26]. The overall MARS scores were used in
the majority of the analyses but patients were also
categorized into high or low adherers (MARS ≥ 26
or < =25) (Fig. 1) as stated in our protocol [22].
Adherence to DMARDs was self-reported by patients
in this study.
2. The Beliefs about Medicines Questionnaire (BMQ)
[27] has Specific and General versions. The BMQ-
Specific assesses patients’ beliefs about a particular
medicine (in this case RA patients’ belief about
DMARDs) and comprises two scales. The 5-item
Specific Necessity scale assesses beliefs about personal
need for DMARDs (a higher score indicates a stronger
belief in personal need for the DMARDs). The Specific
Concerns scale comprises 6 items assessing concerns
about the potential adverse consequences of taking
DMARDs (a higher score indicates stronger concerns
about the potential adverse consequences of
DMARDs). Adjusted Specific Necessity and Concerns
scale scores were calculated by dividing total scores by
the number of items in the scale (possible range 1–5).
A Necessity-Concerns Differential score (NCD;
range −4 to + 4) specific for DMARDs was calculated
by subtracting the adjusted Specific Concerns score
from the adjusted Specific Necessity score. Patients’
NCD scores are positive if the Necessity beliefs are
rated more highly than Concerns and negative if
Concerns are rated more highly than Necessity beliefs.
The BMQ-General comprises two scales that deal
with more general views about medicines as a whole.
The 3-item General Overuse scale assesses beliefs
about the way in which medicines are used by doctors
and the extent to which doctors place too much
emphasis on and trust in medicines (higher scores
indicate higher agreement with the premise that
medicines are overused by doctors). A 5-item General
Harm scale assesses beliefs about the intrinsic
properties of medicines and the degree to which
they are perceived as essentially harmful (with a
higher score indicating stronger views about medicines
being harmful). Again, adjusted scale scores were
calculated by dividing total scores by the number of
items in the scale (possible range 1–5).
3. The Satisfaction with Information about
Medications (SIMS) [21] (in this case RA patients’
satisfaction with information about DMARDs)
comprises 17 items to assess the type of information
that patients require in order to facilitate the safe
self-management of medication. Each item refers to
a particular aspect of their medicines. Examples
include “How to use your medicine” and “What you
should do if you experience unwanted side effects”.
Patients rated their perception of the quality of
information they had received about aspects of
their medicine as ‘too much’, ‘none’, ‘too little’ (all
scored as 0) or ‘none needed’ or ‘about right’
(scored as 1). The SIMS has two components: (1)
‘Action and usage of medicines’ refers to information
received about, for example, how medicines work to
control the condition and how to use medicines (nine
items; scores range from 0 to 9 with a higher score
indicating higher satisfaction) and (2) ‘Potential
problems’ refers to information received about, for
example, what patients should do if experiencing
side effects of the medicine (eight items; scores
range from 0 to 8 with a higher score indicating
higher satisfaction).
4. The Illness Perceptions Questionnaire (IPQ) [28]
measures patients’ perceptions about illness
representations (in this case patients’ illness
perceptions about RA). Patients’ responses are
recorded on a 5–point scale capturing the following
dimensions: the chronicity of RA, a cyclical timeline
(5 items about the fluctuating nature of RA), the
consequences of RA (6 items about the impact of RA),
personal control (6 items representing positive beliefs
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about one’s own ability to control RA), treatment
control (5 items representing a belief that treatment is
effective), illness coherence (5 items about the patient’s
personal understanding of RA), and emotional
representation (6 items about emotions caused by RA).
5. The Health Assessment Questionnaire (HAQ) [29]
measures patients’ functional status and includes
questions related to activities that involve both
upper and lower extremities. The HAQ measures
the ability to perform 20 activities of daily living
with four response categories (without any difficulty
(score 0), with some difficulty (score 1), with much
difficulty (score 2), not being able to do (score 3)). A
higher score indicates a higher level of disability.
In addition, data on socio-economic variables were col-
lected (for example age, gender, occupation and ethnicity)
along with clinical data including the disease activity score
(DAS). Felson et al. [30] the DAS28 data were extracted
from routine follow up clinics around the time when pa-
tients took part in the study (within 1–2 months), the jus-
tification for their use in this study has been outlined in
our study protocol [22].
To accommodate non-English speakers, all question-
naires were translated into Punjabi, Urdu and Hindi using
established guidelines [31]. The translations were audio
recorded. In addition, English versions of the question-
naires were audio recorded and those who read and spoke
English were given a choice of either reading the question-
naires or listening to the audio version. There were 42
patients who requested the audio versions of the ques-
tionnaires (30 who required the Punjabi, Urdu or Hindi
translation and 12 who were from a White background
and requested the English audio tape to be played).
Where the audio version was used, responses were
indicated by patients and the researcher recorded the
patient’s verbal response on the questionnaires. The
Cronbach’s alpha between the responses given by patients
who filled in the questionnaires themselves and patients
who listened to the audio version of the questionnaire and
for whom the researcher marked the patients’ responses
on the questionnaire were checked for reliability of the re-
sponses. There were no inconsistencies between responses.
Reliability was adequate for both English and non-English
versions.
The Index of Multiple Deprivation (IMD) scores is used
widely in England as a measure of deprivation. These
scores are derived from patients’ postcodes to measure
deprivation, higher scores indicating a higher level of
deprivation. They are based on government statistics rating
the overall deprivation of small areas (containing approxi-
mately 1500 people) by combining a number of deprivation
indicators such as local crime, disability, income, education
and housing [32].
The study was approved by the South Birmingham
Research Ethics Committee and written consent was
obtained from all participants.
Statistical analysis
Data were analysed using PASW Statistics software version
18 (SPSS, Chicago, Illinois). Categorical data are sum-
marised as counts and percentages and other data are
presented as means and standard deviation if normally
distributed or as medians and interquartile ranges where
data were skewed. The t-test, Mann–Whitney test, and
Fisher’s exact test were used to compare the demographic
data and BMQ/SIMS/IPQ. Mann–Whitney and Kruskal
Wallis tests were used to compare MARS scores for
categorised variables (followed by Dunn’s test where ap-
propriate). Spearman correlations were used to assess
the association between continuous variables and MARS
scores. A multivariable general linear model was used to
predict overall MARS scores. The variables that were
adjusted in this model were pre-specified in our study
protocol [22]. Linearity was assessed by examination of
the relevant boxplots of MARS scores. Binary logistic
regression was used to carry out analyses of variables with
dichotomous MARS scores. All P values are unadjusted.
Results
Patient characteristics
Patients were recruited from hospital outpatient clinics.
In total, 310 patients were identified and 92 were ex-
cluded due to either cancellation of appointments or the
patient not attending their appointment. We approached
218 patients of whom 38 (17.4 %) declined to take part
in the study, leaving a sample size of 180, a response rate
of 58.1 %. There were no differences noted in ethnicity,
gender or age between patients who were recruited into
the study and those who declined. For logistical reasons
including access to space in which to conduct the research
the White British group (91 patients) were recruited
during the first four months followed by South Asians
(89 patients) during the remaining four months. The
demographic details of patients are shown in Table 1.
South Asian patients were younger (P = 0.006, t-test)
and included a significantly greater proportion of women
than the White British group (P = 0.024, Fisher’s exact
test). There were no significant differences between the
two groups in the level of education received (P = 0.538,
Mann–Whitney). There were differences in employment
status between the two ethnic groups (P = 0.001, Fisher’s
exact test), such that a higher proportion of the South
Asian population were homemakers. There were signifi-
cant differences between patient languages and patients’
self-reported level of education received between the eth-
nic groups. There were more English speaking patients in
the White British group (P < 0.001, Fisher’s exact test) and
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a greater proportion of patients were literate in the White
British group. There were also significant differences in the
languages that patients spoke with their GPs (P < 0.001,
Fisher’s exact test).
Disease related variables
The DAS28 calculated using the CRP (DAS28-CRP) was
higher in the White British patients than the South Asian
patients (P = 0.034, t-test). The disease duration and HAQ
did not differ between the two ethnic groups. Furthermore,
there were no significant differences between DMARDs
that patients were taking amongst the two groups.
Beliefs about medicines and ethnicity
The Specific Concern (P < 0.001, Mann–Whitney), General
Overuse (P < 0.001, Mann–Whitney), and General Harm
(P < 0.001, Mann–Whitney) scores were significantly
higher in the South Asian patients, indicating more nega-
tive views of medicine in general and with regard to their
DMARDs in particular (Table 2). There was no significant
difference between groups in the Specific Necessity scores
for DMARDs. The NCD score was significantly higher in
the White British patients (P < 0.001, Mann–Whitney) indi-
cating that their beliefs that DMARDs were necessary
outweighed their concerns about DMARDs to a greater
extent than was seen for the South Asian patients.
Illness perception and ethnicity
There were significant differences between ethnic groups
in the IPQ domains. Illness coherence (patients’ under-
standing of RA) (P = 0.041, Mann–Whitney) was lower in
the South Asians, indicating that South Asians were more
likely to have a poor understanding of RA (Table 2). The
timeline (patients’ view of disease as acute/chronic; P <
0.001, Mann–Whitney), timeline cyclical (fluctuant dis-
ease; P = 0.017, Mann–Whitney) and emotional repre-
sentation (emotions generated in patients; P = 0.004,
Mann–Whitney) were significantly different between
the two groups indicating that South Asians were more
likely to view RA as short lived rather than chronic, to
experience RA symptoms to be more fluctuating and to
feel more negative emotion related to RA.
Table 1 Demographic data for all participants. Unless otherwise
indicated data are number (%) or median (interquartile range)
White South Asian P value
Number 91 89
Age, years; mean (SD) 57.74 (12.74) 52.46(12.94) 0.006a
Female 56 (61) 69 (77) 0.024b
Level of education 0.538c
Primary 0 (0) 11 (12)
Secondary 49 (54) 33 (38)
College 21 (23) 26 (30)
University 21 (23) 18 (20)
Number of years of education 14 (11–16) 15 (11–17) 0.439c
Employment 0.001b
Full time 33 (36) 31 (35)
Part time 3 (3) 8 (9)
Unemployment 3 (3) 1 (1)
Never employed 0 (0) 1 (1)
Not working due to RA 12 (13) 15 (17)
Not working for other reason 19 (21) 7 (8)
Home maker** 4 (4) 18 (20)
Retired 17 (19) 8 (9)
Preferred language spoken by patient <0.001b
English 91 (100) 51 (57)
Punjabi 0 (0) 29 (33)
Urdu 0 (0) 6 (7)
Hindi 0 (0) 3 (3)
Language spoken with GP <0.001b
English 91 (100) 68 (76)
Punjabi 0 (0) 16 (18)
Urdu 0 (0) 3 (3)
Hindi 0 (0) 2 (2)
Patient Literacy*** <0.001b
Yes 90 (99) 71 (80)
No 1 (1) 18 (20)
Number of years in UK, mean (SD) NA 31.76 (11.6)
DAS CRP, mean (SD) 4.02 (0.83)* 3.76 (0.81)* 0.034a
Disease duration (years) 5 (2–11) 7 (3–13) 0.173c
Oral/biologic DMARDs
Methotrexate 77 (84.6) 81 (91.0) 0.256b
Sulphasalazine 38 (41.8) 42 (47.2) 0.549b
Hydroxychloroquine 10 (11.0) 11 (12.4) 0.820b
Table 1 Demographic data for all participants. Unless otherwise
indicated data are number (%) or median (interquartile range)
(Continued)
Anti-TNF 45 (49.5) 35 (39.3) 0.181b
Other 8 (8.8) 7 (7.9) 1.000b
at-test, bFisher’s exact test, cMann-Whitney, *(CRP was available on 91 White
British, 86 South Asian patients (Level of education; was available on 91 White
British patients, and 88 South Asian patients) **(A homemaker is defined as “a
person who manages the household of his or her own family, especially as a
principal occupation) ***(patients’ ability to read and write in their preferred
language)
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Correlations between SIMS, BMQ and IPQ domains within
each ethnic group
South Asian patients’ views about medicines being over-
used and harmful were significantly correlated with levels
of satisfaction with information about how medicines
work to control RA symptoms and potential issues as-
sociated with DMARDs (action and usage (P = 0.011)
and potential problems (P = 0.004). Whereas only the
correlations between overuse beliefs and the satisfaction
with information about medicines subscales were significant
in the White British patients (action and usage (P = 0.027);
potential problems (P = 0.028) but harm scores were
not (Table 3). The correlation between patients’ percep-
tion of the adequacy of information about their prescribed
DMARD and their beliefs about medicines in general were
stronger in the South Asian patients. White British pa-
tients with higher concerns about the potential adverse
effects of their medications had lower SIMS potential
problems scores (P = 0.031). This was also seen for the
White British group with lower necessity-concern differ-
ential; (P < 0.001).
South Asian patients were more satisfied with informa-
tion about DMARDs if they perceived that they had a
higher degree of personal control over symptoms (P <
0.001), that their treatment was more effective in control-
ling their symptoms (P = 0.014), and that they had a
greater understanding of RA (P < 0.001). The White
British patients who viewed their RA symptoms to be
less fluctuant were more satisfied with the information
received on potential problems (side effects of DMARDs)
(Table 4). White British patients who reported more symp-
toms as associated with RA were less satisfied with infor-
mation that they had received about the action and use of
their DMARDs (P = 0.046). No other significant correla-
tions were found between beliefs about medicines or pa-
tients’ satisfaction with information about RA treatment.
Medication adherence and ethnicity: univariable analysis
The distribution of the MARS scores by ethnicity is
shown in Fig. 1. Using both the overall MARS score
(P = 0.013, Mann–Whitney, as shown in Table 5) and
treating it as a dichotomous variable (P = 0.011, Fisher’s
exact test) there was a significant difference between the
two ethnic groups, with 76.9 % of the White British group
and 58.4 % of the South Asian group being high adherers.
Table 3 Correlation between SIMS and BMQ within each ethnic
group
White British P value South Asian P value
Action and usage
Necessity 0.135 0.201 0.019 0.863
Concern −0.103 0.330 −0.049 0.650
NCD 0.167 0.113 0.009 0.930
Overuse −0.232 0.027 −0.389 <0.001
Harm 0.154 0.146 −0.427 <0.001
Potential Problems
Necessity 0.203 0.054 −0.064 0.551
Concern −0.226 0.031 0.061 0.567
NCD 0.333 <0.001 0.072 0.500
Overuse −0.230 0.028 −0.269 0.011
Harm −0.185 0.078 −0.305 0.004
Table 4 Correlation between SIMS and IPQ domains within
each ethnic group
White British P value South Asian P value
Action and usage
Personal control −0.015 0.887 0.540 <0.001
Treatment control 0.005 0.966 0.259 0.014
Illness coherence 0.091 0.389 0.469 <0.001
Potential Problems
Personal control 0.083 0.431 0.446 <0.001
Treatment control 0.136 0.197 0.270 <0.001
Illness coherence 0.201 0.056 0.413 <0.001
Identity −0.210 0.046 −0.074 0.493
Timeline cyclical −0.289 0.005 0.037 0.732
Table 4 is only showing IPQ domains that were significant
Table 2 Questionnaire data for all participants. Unless otherwise
indicated data are number (%) or median (interquartile range)
Questionnaires
BMQ
Specific Necessity 4.00 (3.80–4.20) 4.00 (4.00–4.00) 0.833c
Specific Concern 3.50 (2.83–4.00) 4.00 (3.83–4.00) <0.001c
NCD 0.33 (0.00–1.10) 0.00 (0.00–0.17) <0.001c
General Overuse 2.67 (2.00–3.33) 3.33 (3.00–4.00) <0.001c
General Harm 2.40 (2.00–3.00) 3.60 (3.00–4.00) <0.001c
SIMS
SIMS action and usage 9 (7–9) 8 (6–9) 0.006c
SIMS potential problems 6 (5–8) 6 (4–8) 0.060c
HAQ 1.25 (1–1.38) 1.25 (1–3) 0.927c
IPQ
Identity 6 (5–8) 6 (5–7) 0.851c
Timeline 24 (23–27) 24 (22–25) <0.001c
Consequences 22 (18–24) 22 (19–24) 0.794c
Personal control 20 (17–23) 19 (17–23) 0.626c
Treatment control 16 (14–18) 16 (15–18) 0.914c
Illness coherence 18 (14–20) 15 (11–20) 0.041c
Timeline cyclical 15 (14–16) 16 (14–16) 0.017c
Emotional representation 22 (18–24) 24 (22–24) 0.004c
cMann-Whitney
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Medication adherence and other variables: univariable
analysis
There were significantly greater adherence scores in the
English speaking patients (both South Asian and White
British) (P < 0.001, Mann–Whitney) (Table 5). Patients
who spoke with their GP in their preferred language had
higher adherence scores (P = 0.002, Mann–Whitney).
71.2 % of those who spoke with GP using their preferred
language were adherent compared with 35.3 % of those
using another language. Patients who were born in the
UK had higher adherence scores than those born in
India (P = 0.015, Dunn’s test). Patients who had higher
levels of education had higher adherence scores (P =
0.014, Spearman correlation). There was no significant dif-
ference between the DAS CRP scores for adherent and
non-adherent patients (P = 0.94). The mean values were
3.89 and 3.90 respectively. The IMD score (deprivation
level) was not associated with adherence scores for either
group (White British, P = 0.320; South Asian, P = 0.503
Spearman correlation).
Patients who had higher General Overuse (P < 0.001,
Spearman correlation) and General Harm scores (P < 0.001,
Spearman correlation) had significantly lower adherence
scores (Table 6). The NCD scores were correlated with
MARS; patients whose perceived need for treatment out-
weighed their concerns about it had higher self-reported ad-
herence scores (P= 0.005, Spearman correlation). SIMS
components, action and usage (P < 0.001, Spearman correl-
ation) and potential problems (P < 0.001, Spearman correl-
ation), were correlated with MARS, with patients who were
more satisfied with information on DMARDs having higher
adherence scores. The two IPQ domains personal control
(P= 0.012, Spearman correlation) and illness coherence (P <
0.001, Spearman correlation) were correlated with MARS,
with patients who had better personal control and under-
standing of the disease having higher adherence scores.
Table 5 Univariable analysis of medication adherence
(demographics and clinical data) (Data for all participants)
Categorical variables Median MARS score
(interquartile range)
P value
Gender 0.982*
M 28 (25–30)
F 28 (24–30)
Level of education 0.083**
Primary 26 (24–27)
Secondary 27 (24–30)
College 28 (25–30)
University 28 (26–30)
Employment 0.219**
Full time 28 (25–30)
Part time 28 (22–30)
Unemployment 30 (28–30)
Never employed 23 (NA)
Not working due to RA 26 (23–30)
Not working for other reason 26 (22–30)
Home maker 26 (24–29)
Retired 29 (26–30)
English spoken by patient <0.001*
Yes 28 (26–30)
No 24 (22–28)
Same language spoken by patient and GP 0.002*
Yes 28 (25–30)
No 24 (22–27)
Patient Literacy level 0.053*
Yes 28 (24–30)
No 24 (24–28)
Ethnicity 0.013*
White British 28 (26–30)
South Asian 26 (23–30)
Oral /Biologic DMARDs
Methotrexate 0.202*
Currently on 28 (24–30)
Not on 26 (25–28)
Sulphasalazine 0.058*
Currently on 26 (23–30)
Not on 28 (25–30)
Hydroxychloroquine 0.621*
Currently on 28 (22–30)
Not on 28 (24–30)
Anti-TNF 0.199*
Currently on 28 (24–30)
Not on 27 (24–30)
Patients’ country of birth 0.014**
Table 5 Univariable analysis of medication adherence
(demographics and clinical data) (Data for all participants)
(Continued)
UK 28a (25–30)
India 26a (22–29)
Pakistan 28 (27–30)
Continuous variables (Spearman correlation)
Age 0.093 0.212
Number of years of education 0.183a 0.014
Number of years in UK −0.177 0.165
Disease duration 0.058 0.438
DAS CRP 0.032 0.674
IMD −0.075 0.315
aMann–Whitney, bKruskal Wallis * India vs UK P=0.0154 (Dunn’s Test) * =
significant at <0.05, ** = significant at <0.01. GP = General Practitioner
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Multivariable analysis
Multivariable analysis was included first to look at age,
sex and all variables significant in the univariable analysis.
There were significant effects of ethnicity and both SIMS
components on adherence scores and there was also a sig-
nificant interaction between ethnicity and the SIMS action
and usage component (Table 7). The effects were similar
to those observed in the univariable analysis. South Asians
had lower adherence scores compared to White British
patients. Patients with higher SIMS scores had higher ad-
herence scores. The interaction between SIMS action and
usage and ethnicity was significant (P = 0.005, F test) with
SIMS action and usage having a greater influence on ad-
herence in South Asian than White British patients. We
repeated the multivariable analysis using dichotomous
MARS scores. The same variables were significant in both
multivariable analyses with the exception that age was
only significant when the MARS was treated as a binary
variable. This suggested older patients were more likely to
report lower adherence (P = 0.038).
Discussion
This study is the first to show lower self-reported adher-
ence amongst South Asian compared with White British
RA patients. Lower self-reported adherence to DMARDs
was associated with dissatisfaction with information about
side effects (SIMS potential problems) in all patients.
There was an interaction between ethnicity and dissatis-
faction with information about both [1] potential prob-
lems associated with DMARDs (SIMS potential problems)
and [2] how DMARDs work to control the condition
(SIMS action and usage), such that dissatisfaction with
information about the action and usage of and potential
problems associated with DMARDs was a greater predictor
of adherence scores in South Asian patients than in the
White British patients. The adherence score was also asso-
ciated with both specific and general beliefs about medi-
cines. Patients who rated their concerns about DMARDS
as high relative to their ratings of their personal need for
DMARDs to control RA and maintain present and future
health, reported lower self-reported adherence. DMARD
adherence scores were also correlated with more negative
views of medicines in general, with low adherence scores
associated with a perception that medicines are fundamen-
tally harmful and overused by doctors. The level of satisfac-
tion with information correlated with negative beliefs about
medicines and illness representation of their RA. South
Asian patients had higher levels of satisfaction with infor-
mation about DMARDs if they had a higher degree of
personal control over symptoms.
Previous studies investigating the beliefs about medi-
cines held by RA patients also found that patients had
strong concerns about potential side effects of DMARDs
[12, 19, 33]. Neame and Hammond [12] reported concern
scores to be associated with non-adherence and our find-
ings suggest that concerns about potential adverse conse-
quences of DMARDs may be particularly prevalent in
South Asian patients. This is consistent with our previous
work where South Asian patients reported higher concerns
about their DMARDs [14]. In another RA study, Treharne
et al. [34] found that strong beliefs about the necessity of
medications and believing medications not to be harmful
predicted higher self-reported adherence but data were only
available for White patients. In common with a previous
study of medication beliefs and adherence in RA, we found
no association, in our multivariable analysis, between self-
reported adherence and sociodemographic factors (age,
gender, level of education) or whether English was spoken
by the patient. A study conducted in Bradford, UK, [35],
suggested that the difficulty communicating in English ex-
perienced by some first-generation South Asian females
was a barrier to understanding the disease process and the
need for long term DMARD therapy. As a result, in that
study, South Asian patients discontinued their DMARDs
sooner than the non-South Asian population however,
there were limited data on clinical outcomes. Although the
DAS28 scores were slightly lower in the South Asian pa-
tients, it is difficult to draw significant conclusions related
to disease severity based on a single DAS28 score. Longitu-
dinal work is required to measure long term outcomes.
Table 6 Univariable analysis of medication adherence
(questionnaires) (Data for all participants)
Questionnaires
BMQ
Specific Necessity 0.052 0.489
Specific Concern −0.114 0.127
NCD 0.209** 0.005
General Overuse −0.309** <0.001
General Harm −0.300** <0.001
SIMS
SIMS action and usage 0.386** <0.001
SIMS potential problems 0.469** <0.001
HAQ −0.055 0.465
IPQ
IPQ Identity −0.126 0.092
IPQ Timeline 0.071 0.343
IPQ Consequences −0.052 0.492
IPQ Personal control 0.187* 0.012
IPQ Treatment control 0.085 0.258
IPQ Illness coherence 0.294** <0.001
IPQ Timeline cyclical −0.138 0.065
IPQ Emotional representation −0.097 0.197
* = significant at <0.05, ** = significant at <0.01
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Our results suggest that dissatisfaction with informa-
tion may occur because patients’ rationale for the long
term use of DMARDs may not match with that of the
health professional [17, 24, 36]. For example, the South
Asian patients in our study who viewed RA to be a short
lived condition may need to be provided with a convincing
rationale for taking long-term treatment consistently even
when their RA symptoms fluctuate. The association be-
tween beliefs and adherence seen within the current
sample is consistent with theoretical predictions regarding
the importance of beliefs about medicines in patients with
RA [22]. These have been described in relation to the
literature in other disease areas and the findings provide
further support for the Necessity-Concerns framework in
non-adherence, which suggests that these common-sense
appraisals of treatment can impact on adherence [37].
Furthermore, Horne and Weinman [17] for example, re-
ported that patients with asthma who were non-adherent
had more doubts about the necessity of their medication
and concerns about its adverse effects and believed
asthma had a more negative impact on their life. Petrie
et al. [38] demonstrated that it is possible to alter illness
behaviours through targeting illness perceptions by provid-
ing a common-sense rationale for treatment and illness.
Beliefs held by RA patients about treatment might arise
from a range of factors including personal experience,
illness representations and culture, as well as from infor-
mation provided by healthcare professionals [39]. Further-
more, data in studies of RA [35], cardiovascular disease
[40–42] and diabetes [43–47] in South Asian patients have
cited cultural factors as an influence on patients’ response
to illness and treatments. Work is now required in RA to
build interventions that are based on theoretical models.
For example, using the Necessity-Concerns framework and
illness representations model at early stages of the diagno-
sis and initiation of treatment, may help to identify behav-
iours that influence decisions to take DMARDs and reduce
non-adherence behaviours early.
Our study has a number of limitations including the
fact that adherence was self-reported. We acknowledge
that using a single approach to collect data on adherence
is a limitation of this study. It is widely recognised that
all individual approaches to measuring adherence have
their specific limitations. For example, pharmacy refill
Table 7 Multivariable analysis of medication adherence (Data for all participants)
B Confidence interval P value R2 for model
0.328
Age (years) −0.012 −0.049–(0.025) 0.523
Gender (male) −0.754 −1.754–(0.245) 0.138
Number of years education −0.022 −0.095–(0.050) 0.540
English spoken by patient −0.492 −2.384–(1.399) 0.608
Same language spoken by patient and GP 1.447 −0.466–(3.360) 0.137
Born in Pakistana 2.071 −0.023–(4.165) 0.053
Born in Indiaa 1.575 −0.158–(3.307) 0.075
Ethnicity (White British) 7.333 2.924–(11.743) 0.001*
BMQ
NCD 0.079 −0.590–(0.749) 0.815
General Overuse −0.193 −0.478–(0.092) 0.183
General Harm −0.049 −0.250–(0.153) 0.635
SIMS
SIMS action and usage (South Asian patients) 0.560 0.163–(0.958) 0.006*
SIMS action and usage (White British patients) −0.202 −0.595–(0.191) 0.311
SIMS potential problems 0.428 0.217–(0.639) <0.001**
IPQ
IPQ Personal control −0.070 −0.205–(0.066) 0.310
IPQ Illness coherence 0.086 −0.038–(0.211) 0.174
Interaction
SIMS action and usage x ethnicityb 0.005*
a= reference category born in UK. bThe significant interaction indicates that the effect of SIMS action and usage varies with ethnic group: hence two separate sets
of values for South Asian and White British patients. * = significant at <0.01 ** = significant at <0.001
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data only index whether patients collect their medication,
not whether they take it [9], while electronic monitoring
methods can be expensive and inconvenient for patients
to use (e.g. due to the size of pill caps [9]). The method-
ology to be used to measure adherence in the present
study was discussed with our Patient Research Partners
who recommended a self-report strategy [22]. Future
studies in this population may need to combine a self-
report measure with other techniques [48]. Secondly, this
is the first study to have used a number of questionnaires
(SIMS, IPQ and MARS) that were independently trans-
lated into three languages for the South Asian population.
It is possible that some views specific to this population
are not captured via these questionnaires. For example, in
our previous qualitative work, patients’ views about dis-
ease, medicines and desired outcomes were influenced by
their health beliefs [14, 49]. Furthermore, patients who
responded to questionnaires via audio tapes could have
missed the opportunity to record their own responses.
Thirdly, this study was cross-sectional, preventing us
from drawing conclusions regarding which factors were
causally related to non-adherence especially the DAS
scores. Fourthly, patients’ views about taking medications
for other co-morbidities were not recorded; we acknow-
ledge that this may have affected the views about taking
DMARDs and would be an interesting issue to explore
in future research. Finally, data were not collected on the
delay from the time their RA began in patients commen-
cing DMARDs; this could have been an important factor
in explaining the different patterns of adherence as we
have previously shown that RA patients of South Asian
origin delay seeking medical help for longer than non-
South Asians patients [15].
Despite these limitations, this study provides novel and
useful insight into RA patients’ poor adherence in the two
ethnic groups studied.
Conclusions
In conclusion, non-adherence to DMARDs was associated
with patients’ beliefs about DMARDs, their illness repre-
sentations and views about medicines in general together
with their satisfaction with the type and amount of infor-
mation they had received about DMARDs. This varied
between the two ethnic groups. Our data suggest the
following recommendations for clinical practice; (1)
Clinicians should engage with individual patients to
identify specific factors that may be responsible for
poor adherence behaviours. (2) Clinicians should ask
patients about medication adherence during every con-
sultation. (3) Clinicians should use tailored educational
materials that provide an in-depth but comprehensible
explanation of RA, the rationale for using DMARDs to
control disease activity in RA and the consequences of
poor adherence.
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